Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,593.24
(
1.33%
)
US TECH 100
23,540.00
(
1.11%
)
Dow Jones
46,312.62
(
1.61%
)
Brent Oil
97.94
(
-9.42%
)
Bitcoin
70,976.96
(
4.63%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 180950

Tuesday, 01/27/2015 4:13:49 PM

Tuesday, January 27, 2015 4:13:49 PM

Post# of 257269
AMGN submits sNDA & MAA for Kyprolis in second-line MM:

http://finance.yahoo.com/news/amgen-submits-applications-us-europe-210200219.html

In the US, Kyprolis is currently approved for third-line MM under an AA submission based on only the response rate; the sNDA seeks to expand the label and to obtain full-fledged rather than conditional approval.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today